Diseases, Conditions, Syndromes

Denosumab promising for TDT-induced osteoporosis treatment

(HealthDay)—Denosumab (DNM), a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), may be beneficial for managing transfusion-dependent thalassemia (TDT)-induced osteoporosis, ...


Durvalumab extends survival in stage III non-small cell lung CA

(HealthDay)—Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, ...

page 1 from 23